Cardiovascular disease Archives

News and Trends 20 Mar 2017

French Biotech fails Second Phase II Trial for Cardiovascular Disease

Cerenis therapeutic’s lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome (ACS). The French-based Biotech Cerenis is developing therapies for the treatment of cardiovascular and metabolic diseases. The company now presented data on its lead candidate CER-001, which was investigated in a Phase II study for the treatment of patients with post-acute […]

March 20, 2017 - 3 minutesmins - By Melanie De Almeida

Tigenix AlloCSC 01 stem cell therapy AMI

News and Trends 13 Mar 2017

New Cardiac Stem Cell Therapy passes Phase I/II Trials

TiGenix announces positive one-year results for its phase I/II trial of donor-derived cardiac stem cell therapy in acute myocardial infarction (AMI). The Belgian biotech TiGenix is developing allogeneic stem cell therapies. Now the company has announced that its cardiac stem cell therapy AlloCSC-01 reached its primary endpoints in a phase I/II trial. In 2015, the company acquired Coretherapix in a €292M deal for its allogeneic cardiac stem […]

March 13, 2017 - 3 minutesmins - By Melanie De Almeida

More News! 9 Feb 2017

After its First Success, the Virtual Biotech Team is Back at it Again

SuperX has raised €10.3M ($11M) in Series A from Medicxi and J&J Innovation to develop anticoagulant antibodies for stroke and heart attacks. The team behind XO1, which was acquired by J&J’s Janssen back in 2015, is repeating the whole process again. Their new company, SuperX, is also focused on the discovery of anticoagulant antibodies to treat […]

February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 8 Feb 2017

The First Stroke Drug in Decades? French Biotech gets closer to the Clinic

Acticor Biotech has raised €1.5M from CapDecisif Management, which will help its candidate for acute ischemic stroke enter Phase I trials. Acticor Biotech is a spin-off from the French National Institute of Health and Medical Research (Inserm) focusing on treating the acute phase of ischemic stroke, which occurs within the first few hours. The French VC firm CapDecisif Management has seen promise in […]

February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Jan 2017

New British Biotech-Academia Alliance takes on Cardiovascular Disease

Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based in London, develops drugs against historically undruggable G protein-coupled receptors (GPCRs). The company has now announced a new research collaboration with the University of Cambridge focusing on a specific GPCR, the apelin receptor. Heptares will support a […]

January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Jan 2017

Evotec launches New Biotech to tackle the Most Deadly Diseases

Evotec has backed the foundation of Fibrocor, a Canadian company that will work on fibrosis, the underlying cause of some of the most deadly diseases. Fibrocor was launched yesterday in Toronto with €2M (CDN 2.8M) from the successful German biotech CRO Evotec and the Canadian non-profit MaRS Innovation. Evotec will provide all drug discovery activities […]

January 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Dec 2016

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […]

December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Dec 2016

European Pharma closes 2016 by launching new Biotech Startups

Big pharma is already head on starting 2017 with a bang. Pfizer and Bayer are launching US-based startups in oncolytic virus and stem cell therapies. Pharma is wrapping up 2016 by investing in a pair of new ventures. Bayer and Versant have invested $225M to launch BlueRock Therapeutics, which will focus on CNS and cardiovascular diseases. This comes […]

December 13, 2016 - 2 minutesmins - By Evelyn Warner

sloth crossing the road Scenic Shutterbug fi

News and Trends 2 Dec 2016

Stories We Didn’t Cover: MDMA in Phase III, Another Death for Carmat

Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Sanofi has acquired Warp Drive Bio’s antibiotics program, which was born out of […]

December 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 17 Nov 2016

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

UniQure just announced a new R&D plan designed to save up to €27M over the next two years. Will the new strategy be enough to pull it out of its down spiral? UniQure is a Dutch biotech famous for launching Glybera, the first commercial gene therapy worldwide. However, the huge price of the treatment has […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Nov 2016

These companies want to use Stem Cells to improve Drug Safety

Axiogenesis and Metrion Biosciences will use stem cells to improve preclinical neurotoxicity and cardiac safety testing, a feat that can significantly reduce the time and cost of drug discovery and clinical development. Axiogenesis is a Biotech from Cologne, Germany, that develops cell lines derived from induced pluripotent stem cells (iPSCs) for preclinical applications. The company […]

November 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 01 at 3.27.32 PM e1478010517232

News and Trends 1 Nov 2016

Novo Nordisk pressured into Dropping Needle-Free Oral Insulin

Needle-free diabetes will have to wait: payers are pressuring pharma to provide lower medication prices, and Novo Nordisk has responded by redirecting its R&D strategy into more innovative research. Despite its position as a world leader in diabetes, Novo Nordisk seems to be hitting a rough patch: the big pharma is reducing its profit and […]

November 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us